295 related articles for article (PubMed ID: 31416195)
1. The PTEN Tumor Suppressor Gene in Soft Tissue Sarcoma.
Stefano S; Giovanni S
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31416195
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential.
Francis P; Namløs HM; Müller C; Edén P; Fernebro J; Berner JM; Bjerkehagen B; Akerman M; Bendahl PO; Isinger A; Rydholm A; Myklebost O; Nilbert M
BMC Genomics; 2007 Mar; 8():73. PubMed ID: 17359542
[TBL] [Abstract][Full Text] [Related]
3. Establishment of an Academic Tissue Microarray Platform as a Tool for Soft Tissue Sarcoma Research.
Lee CJ; Wozniak A; Van Cann T; Timmermans I; Wellens J; Vanleeuw U; Briaire-de Bruijn IH; Britschgi C; Bovée JVMG; Zlobec I; Sciot R; Schöffski P
Sarcoma; 2021; 2021():6675260. PubMed ID: 34413700
[TBL] [Abstract][Full Text] [Related]
4. Genetic and epigenetic alterations of the PTEN gene in soft tissue sarcomas.
Kawaguchi K; Oda Y; Saito T; Takahira T; Yamamoto H; Tamiya S; Iwamoto Y; Tsuneyoshi M
Hum Pathol; 2005 Apr; 36(4):357-63. PubMed ID: 15891996
[TBL] [Abstract][Full Text] [Related]
5. Soft tissue sarcoma subtypes exhibit distinct patterns of acquired uniparental disomy.
Tuna M; Ju Z; Amos CI; Mills GB
BMC Med Genomics; 2012 Dec; 5():60. PubMed ID: 23217126
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological characteristics and prognostic factors of T1 (≤5 cm) soft tissue sarcoma -- a comparative study with T2 (>5 cm) soft tissue sarcoma.
Kang S; Han I; Lee S; Kim W; Kim H
Eur J Surg Oncol; 2014 Apr; 40(4):406-11. PubMed ID: 24388741
[TBL] [Abstract][Full Text] [Related]
7. Anaplastic lymphoma kinase protein expression, genetic abnormalities, and phosphorylation in soft tissue tumors: Phosphorylation is associated with recurrent metastasis.
Ishibashi Y; Miyoshi H; Hiraoka K; Arakawa F; Haraguchi T; Nakashima S; Hashiguchi T; Shoda T; Hamada T; Okawa T; Higuchi F; Shiba N; Nagata K; Ohshima K
Oncol Rep; 2015 Apr; 33(4):1667-74. PubMed ID: 25683346
[TBL] [Abstract][Full Text] [Related]
8. A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis.
Bui NQ; Przybyl J; Trabucco SE; Frampton G; Hastie T; van de Rijn M; Ganjoo KN
Clin Sarcoma Res; 2019; 9():12. PubMed ID: 31528332
[TBL] [Abstract][Full Text] [Related]
9. Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometry.
Milighetti M; Krasny L; Lee ATJ; Morani G; Szecsei C; Chen Y; Guljar N; McCarthy F; Wilding CP; Arthur A; Fisher C; Judson I; Thway K; Cheang MCU; Jones RL; Huang PH
J Proteomics; 2021 Jun; 241():104236. PubMed ID: 33895336
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
[TBL] [Abstract][Full Text] [Related]
11. Quantitative proteomic studies addressing unmet clinical needs in sarcoma.
Connolly EA; Grimison PS; Horvath LG; Robinson PJ; Reddel RR
Front Oncol; 2023; 13():1126736. PubMed ID: 37197427
[TBL] [Abstract][Full Text] [Related]
12. Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing.
Cornillie J; Wozniak A; Li H; Wang Y; Boeckx B; Gebreyohannes YK; Wellens J; Vanleeuw U; Hompes D; Stas M; Sinnaeve F; Wafa H; Lambrechts D; Debiec-Rychter M; Sciot R; Schöffski P
Mol Cancer Ther; 2019 Jun; 18(6):1168-1178. PubMed ID: 30962320
[TBL] [Abstract][Full Text] [Related]
13. Soft tissue sarcomas with complex genomic profiles.
Guillou L; Aurias A
Virchows Arch; 2010 Feb; 456(2):201-17. PubMed ID: 20217954
[TBL] [Abstract][Full Text] [Related]
14. Alterations of cancer-related genes in soft tissue sarcomas: hypermethylation of RASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma.
Seidel C; Bartel F; Rastetter M; Bluemke K; Wurl P; Taubert H; Dammann R
Int J Cancer; 2005 Apr; 114(3):442-7. PubMed ID: 15551306
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts.
Cornillie J; Wozniak A; Van Renterghem B; Van Winkel N; Wellens J; Gebreyohannes YK; Debiec-Rychter M; Sciot R; Hompes D; Schöffski P
BMC Cancer; 2019 Jul; 19(1):724. PubMed ID: 31331295
[TBL] [Abstract][Full Text] [Related]
16. Pleomorphic Sarcomas: The State of the Art.
Carvalho SD; Pissaloux D; Crombé A; Coindre JM; Le Loarer F
Surg Pathol Clin; 2019 Mar; 12(1):63-105. PubMed ID: 30709449
[TBL] [Abstract][Full Text] [Related]
17. Determining the prognostic significance of alternative splicing events in soft tissue sarcoma using data from The Cancer Genome Atlas.
Yang X; Huang WT; He RQ; Ma J; Lin P; Xie ZC; Ma FC; Chen G
J Transl Med; 2019 Aug; 17(1):283. PubMed ID: 31443718
[TBL] [Abstract][Full Text] [Related]
18. Potential application of genomic profiling for the diagnosis and treatment of patients with sarcoma.
Xu L; Xie X; Shi X; Zhang P; Liu A; Wang J; Zhang B
Oncol Lett; 2021 May; 21(5):353. PubMed ID: 33747210
[TBL] [Abstract][Full Text] [Related]
19. The PTEN tumor suppressor gene and its role in lymphoma pathogenesis.
Wang X; Huang H; Young KH
Aging (Albany NY); 2015 Dec; 7(12):1032-49. PubMed ID: 26655726
[TBL] [Abstract][Full Text] [Related]
20. Involvement of tumor suppressors PTEN and p53 in the formation of multiple subtypes of liposarcoma.
Puzio-Kuter AM; Laddha SV; Castillo-Martin M; Sun Y; Cordon-Cardo C; Chan CS; Levine AJ
Cell Death Differ; 2015 Nov; 22(11):1785-91. PubMed ID: 25822339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
